Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2019-08-07 Report Publication Anno…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC SE TO REPORT FIRST HALF-YEAR 2019 RESULTS ON 14 AUGUST 2019
Report Publication Announcement Classification · 99% confidence The document is a short news release dated August 7, 2019, announcing that EVOTEC SE will report its financial results for the 'first half-year 2019' on August 14, 2019. It explicitly details the date, time, and dial-in numbers for the associated conference call to discuss these results. Since this document is an announcement *about* the upcoming release of periodic financial results (First Half-Year 2019), and not the comprehensive report itself, it fits the definition of an Earnings Release (ER) or potentially a Report Publication Announcement (RPA). Given that it focuses on the upcoming release of period-specific financial results and includes conference call details, 'ER' (Earnings Release) is the most appropriate primary classification, even though it precedes the actual release. It is not the full Interim Report (IR) itself. The 'Menu vs Meal' rule suggests RPA if it were just a link, but this provides substantial context about the results being announced, leaning towards ER.
2019-08-07 English
Evotec SE: New IMI project 'GNA Now' kicks off its battle against antimicrobial resistance
Regulatory Filings Classification · 95% confidence The document is a press release dated August 1, 2019, announcing a new partnership ('GNA Now' project) between Evotec SE and Lygature, funded by the Innovative Medicines Initiative (IMI), to combat antimicrobial resistance. It details the scope, partners, goals, and funding structure of this R&D consortium. This type of announcement, detailing strategic collaborations, funding awards, and scientific progress updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general corporate news or regulatory announcements. Since it is a news release detailing a specific corporate action (a major R&D alliance and funding), and it doesn't fit the specific definitions for ER (Earnings Release), CAP (Financing Update), or LTR (Legal Proceedings), the most appropriate general category for a significant, non-financial-period-specific corporate update that is disseminated via news wire is Regulatory Filings (RNS), which serves as a broad category for official company news releases that don't fit elsewhere. Given the context of a major partnership announcement, it is a form of regulatory disclosure/news release.
2019-08-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of announcement, detailing changes in the total number of voting rights, is a specific regulatory disclosure. While it relates to capital structure, the core focus is the official notification of the voting rights count. This fits best under the category for official regulatory announcements that are not standard financial reports or specific insider trades. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for mandatory, non-standard regulatory disclosures like this, especially since there isn't a specific code for 'Total Voting Rights Announcement'. It is not a full report (10-K, IR), nor a dividend notice (DIV), nor a share repurchase (POS).
2019-07-31 English
EVOTEC SE: P2X3 ANTAGONIST DEMONSTRATES EFFICACY AGAINST REFRACTORY CHRONIC COUGH IN PHASE II (POC)
Regulatory Filings Classification · 95% confidence The document is a press release dated July 25, 2019, announcing positive Phase II Proof-of-Concept (POC) results for a P2X3 antagonist (BAY1817080) developed in partnership with Bayer. It details clinical study outcomes (endpoints met, safety profile) and mentions future milestones (Phase III start). This content is characteristic of an announcement detailing clinical trial progress and partnership updates, which is typically released as an Earnings Release (ER) or a general Regulatory Filing (RNS) if no other specific category fits perfectly. Since it is a specific announcement of clinical trial success and partnership progress, it is not a full Annual Report (10-K), Interim Report (IR), or a Call Transcript (CT). It is not a formal Earnings Release (ER) which usually focuses on revenue/profit figures, but rather a specific operational/pipeline update. Given the nature of reporting clinical trial success, it falls best under the general 'Regulatory Filings' (RNS) category as a corporate news announcement disseminated via DGAP, or potentially an 'Earnings Release' (ER) if the company treats pipeline news as part of its periodic results disclosure, but RNS is the safest general category for non-standard operational news releases. Upon review of the definitions, this is a specific corporate news announcement about a drug trial success. It is not a DEF 14A (Remuneration), DIRS (Insider Trading), or DIV (Dividend). It is a significant operational update. Since it is not a formal financial report (10-K, IR) or a presentation (IP), and it is not explicitly announcing the *release* of a report (RPA), the most appropriate general category for significant, non-financial-statement corporate news disseminated via DGAP is RNS (Regulatory Filings/General Announcement).
2019-07-25 English
Evotec SE: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Regulatory Filings Classification · 95% confidence The document is labeled as an 'Ad-hoc' release dated July 25, 2019, disclosing 'inside information acc. to Article 17 MAR'. It details positive Phase II clinical trial results for a drug candidate developed under an alliance between Evotec and Bayer, mentioning potential future milestone payments. This type of announcement, which conveys material, non-public information regarding clinical development progress and potential financial impact outside of standard periodic financial reports (like 10-K or IR), fits best under the general category for regulatory announcements that don't fit elsewhere, which is 'Regulatory Filings' (RNS). It is not an Earnings Release (ER), a Call Transcript (CT), or a specific financial report like 10-K or IR. Given its nature as a mandatory disclosure under EU regulations (MAR), RNS is the most appropriate general classification.
2019-07-25 English
EVOTEC EXPANDS ITS IPSC DISCOVERY PLATFORM
Regulatory Filings Classification · 100% confidence The document is a 'News Details' announcement from Evotec SE dated July 15, 2019, disseminated via DGAP-News. The content describes a corporate action: the acquisition of assets from Ncardia AG to expand Evotec's iPSC discovery platform. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific announcement regarding a strategic business development (M&A activity, although it's an asset acquisition, it falls under strategic transactions). Since there is no specific code for 'Asset Acquisition Announcement' and it is a significant corporate event announcement, it is best classified as a general Regulatory Filing (RNS) or potentially M&A Activity (TAR). Given the nature of the announcement (acquisition of IP, cells, and team), TAR (Merger/Takeover Activity) is a close fit, but RNS is the broader category for general corporate news disseminated via services like DGAP that don't fit the highly specific financial report codes. However, since the event is a transaction involving acquiring assets/IP, TAR is more specific than RNS. Let's re-evaluate the definitions. TAR is for 'merger proposals or takeover bids'. This is an asset acquisition, which is related but not strictly a merger/takeover. Since it is a significant corporate event announcement disseminated via a news service (DGAP), and it doesn't fit ER, IR, 10-K, or DIRS, RNS (Regulatory Filings / General Regulatory Announcements) is the most appropriate fallback for significant, non-financial-statement corporate news.
2019-07-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.